Opinion|Videos|November 4, 2024
Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis
Panelists discuss how various approved and investigational FcRn-targeting agents differ in their mechanisms of action for treating generalized myasthenia gravis (gMG).
Advertisement
Video content above is prompted by the following:
- A number of agents targeting the neonatal Fc receptor (FcRn) have recently been approved or are under investigation to treat gMG. What are the differences regarding mechanism of action among the following approved or investigational FcRn-targeting agents?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
- Setting Realistic Expectations for Antiamyloid Therapeutics
September 11th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity
2
Daridorexant Provides Relief for Insomnia in Women During Menopausal Transition
3
RELIEV-CM Pilot Study Data Further Supports ShiraTronics’ Neuromodulation Device to Treat Chronic Migraine
4
Insights Into the Neurobiology of Stuttering From 2025 STARS Conference: Shahriar SheikhBahaei, PhD
5